Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the tears of patients with allergic conjunctivitis are known to have increased concentrations of cytokines and allergic mediators. The objective of this study is to determine if the positive effects of Veramyst nasal spray on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the amount of allergic mediators detected in their tears.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
20
2 sprays each nostril every morning for 2 weeks
2 sprays each nostril every morning for 2 weeks
Rush University Medical Center
Chicago, Illinois, United States
Eosinophilic Cationic Protein (ECP) Levels
Tear samples from the participants eyes were collect and were to be used for measuring esinophilic cationic prtein, but this was not measured because the volume of tears were to low.
Time frame: Samples taken at initial visit & 2 week follow-up
Histamine Content in the Tears Was Measured.
Tear samples were assayed for histamine by ELISA
Time frame: Samples taken at initial visit & 2 week follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.